Phase II Trial of Prednimustine®, Leo‐1031 (NSC‐134087) in Acute Non‐Lymphocytic Leukaemia

Publisher Website
Google Scholar
Abstract
Prednimustine, a chlorambucil ester of prednisolone, as a single drug was used to treat 18 patients with acute non-lymphocytic leukemia [ANLL]. Five patients responded with falling blast counts in peripheral blood, but only 1 obtained complete remission of 3 mo. duration. Since activity of prednimustine is lower than that of other commonly used drugs in ANLL, future studies should concentrate on other aspects, such as treatment of patients with steroid receptor-positive blast cells or other types of leukemia.